These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23740364)

  • 21. Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population.
    Currie CJ; McEwan P; Emmas C; Morgan CL; Peters JR
    Curr Med Res Opin; 2005 Dec; 21(12):1905-13. PubMed ID: 16368039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study.
    Naganuma M; Shiga T; Sato K; Murasaki K; Hashiguchi M; Mochizuki M; Hagiwara N
    Thromb Res; 2012 Jul; 130(1):21-6. PubMed ID: 22137743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes.
    Witt DM; Delate T; Hylek EM; Clark NP; Crowther MA; Dentali F; Ageno W; Martinez KD; Garcia DA
    Thromb Res; 2013; 132(6):770-5. PubMed ID: 24521790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
    White HD; Gruber M; Feyzi J; Kaatz S; Tse HF; Husted S; Albers GW
    Arch Intern Med; 2007 Feb; 167(3):239-45. PubMed ID: 17296878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A re-appraisal of warfarin control in the treatment of deep vein thrombosis and / or pulmonary embolism.
    Amiwero C; Campbell IA; Prescott RJ
    Afr Health Sci; 2009 Sep; 9(3):179-85. PubMed ID: 20589148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonadherence with INR monitoring and anticoagulant complications.
    Witt DM; Delate T; Clark NP; Garcia DA; Hylek EM; Ageno W; Dentali F; Crowther MA
    Thromb Res; 2013 Aug; 132(2):e124-30. PubMed ID: 23800635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft.
    El-Chami MF; Kilgo P; Thourani V; Lattouf OM; Delurgio DB; Guyton RA; Leon AR; Puskas JD
    J Am Coll Cardiol; 2010 Mar; 55(13):1370-6. PubMed ID: 20338499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
    Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
    J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study.
    Dentali F; Pignatelli P; Malato A; Poli D; Di Minno MN; Di Gennaro L; Rancan E; Pastori D; Grifoni E; Squizzato A; Siragusa S; Di Minno G; Ageno W
    Am J Hematol; 2012 Apr; 87(4):384-7. PubMed ID: 22367852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism.
    Nordstrom BL; Kachroo S; Fraeman KH; Nutescu EA; Schein JR; Fisher A; Bookhart BK
    Curr Med Res Opin; 2011 Oct; 27(10):1973-85. PubMed ID: 21919556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin.
    Kim JS; Jongnarangsin K; Latchamsetty R; Chugh A; Ghanbari H; Crawford T; Yokokawa M; Good E; Bogun F; Pelosi F; Morady F; Oral H
    Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):302-9. PubMed ID: 23443620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Warfarin interactions with antibiotics in the ambulatory care setting.
    Clark NP; Delate T; Riggs CS; Witt DM; Hylek EM; Garcia DA; Ageno W; Dentali F; Crowther MA;
    JAMA Intern Med; 2014 Mar; 174(3):409-16. PubMed ID: 24445404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The necessity to assess anticoagulation status in elderly injured patients.
    Williams TM; Sadjadi J; Harken AH; Victorino GP
    J Trauma; 2008 Oct; 65(4):772-6; discussion 776-7. PubMed ID: 18849789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events.
    Klok FA; Zondag W; van Kralingen KW; van Dijk AP; Tamsma JT; Heyning FH; Vliegen HW; Huisman MV
    Am J Respir Crit Care Med; 2010 Mar; 181(5):501-6. PubMed ID: 19965808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study.
    O'Donnell M; Oczkowski W; Fang J; Kearon C; Silva J; Bradley C; Guyatt G; Gould L; D'Uva C; Kapral M; Silver F;
    Lancet Neurol; 2006 Sep; 5(9):749-54. PubMed ID: 16914403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
    Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.